Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

DNL593

Other · developed by Denali Therapeutics

Phase 1/2 Most advanced trial

DNLI Developer

1 Registered trials

What is DNL593?

DNL593 is an investigational agent studied in frontotemporal dementia, with ascending single doses in healthy participants and multiple doses in participants with the disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: Denali Therapeutics Inc. (DNLI)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05262023	Phase 1/2	Frontotemporal Dementia	Active not recruiting	DNLI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Frontotemporal Dementia

More from Denali Therapeutics

Tividenofusp Alfa FDA approved DNL126 Phase 1/2 DNL201 Phase 1 DNL343 Phase 2/3 DNL628 Phase 1 DNL747 Phase 1 DNL919 Phase 1 DNL921 Phase 1 DNL952 Phase 1

Sources

ClinicalTrials.gov NCT05262023

Updated Oct 11, 2026. Something wrong or missing? Report it on the DNLI page.

Follow DNLI, the company behind DNL593

See DNLI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DNLI catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z